Acoustic Neuroma Imaging Guidelines

Primary Imaging Recommendation

The American Academy of Otolaryngology-Head and Neck Surgery recommends MRI with gadolinium contrast as the definitive first-line imaging modality for evaluating suspected acoustic neuroma, offering superior sensitivity and specificity compared to all other diagnostic approaches 1, 4, 5, 6
The optimal MRI protocol should include axial submillimetric heavily T2-weighted sequences, T1-weighted sequences before and after gadolinium administration, standard T2-weighted sequences, diffusion-weighted imaging, and FLAIR sequences to visualize the vestibulocochlear nerve and rule out brainstem pathology 1, 2, 3

High-resolution T2-weighted or T2-star-weighted MRI without gadolinium has demonstrated high sensitivity and may be considered as a cost-effective screening alternative, though gadolinium-enhanced T1-weighted imaging remains the gold standard 4, 5
For patients unable to undergo MRI, fine-cut CT of temporal bones with contrast or auditory brainstem response testing may be used as alternative approaches, but with lower sensitivity and specificity 4, 7

MRI has the highest diagnostic yield of any test for acoustic neuroma, with overall pathogenic abnormality rates of 7-13.75% in patients with sudden sensorineural hearing loss 4
Acoustic neuromas characteristically present as a solid nodular mass with intracanalicular component in the IAC, often causing canal widening, and are isointense on T1-weighted imaging with strong gadolinium enhancement 1, 2, 3

MRI is more cost-effective than ABR followed by MRI for acoustic neuroma diagnosis, with economic analyses demonstrating that non-contrast MRI screening protocols or direct gadolinium-enhanced MRI are more cost-effective than traditional ABR-based algorithms 4

The American College of Radiology recommends against ordering routine head CT as the initial imaging study, as it provides inadequate visualization and unnecessary radiation exposure 6, 7
The American Academy of Otolaryngology-Head and Neck Surgery advises against relying on ABR alone for screening, as sensitivity for small tumors is unacceptably low (8-42%) 4